UBS Group
ANIK icon

UBS Group’s Anika Therapeutics ANIK Stock Holding History

UBS Group’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-800
Closed -$33K – 8456
2015
Q1 		$33K Sell
800
-100
-11% -$4.04K ﹤0.01% 6448
2014
Q4 		$37K Buy
+900
New +$35.2K ﹤0.01% 6855

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

UBS Group's ANIK Position: Q1 2026 in Review

UBS Group increased its Anika Therapeutics (ANIK) stake by 366% in Q1 2026, buying an estimated $1.21M and bringing the position to 133,074 shares worth $1.93M. The position accounts for ﹤0.01% of the portfolio, ranked #5007.

UBS Group first reported a position in ANIK in Q4 2014 and has held it in 46 quarters since. The position peaked at $3.3M in Q1 2019. 130 funds tracked by Wall St. Rank hold ANIK as of Q1 2026.

  • UBS Group held 133,074 shares of Anika Therapeutics worth $1.93M as of Q1 2026.
  • UBS Group bought 104,529 Anika Therapeutics shares in Q1 2026, an estimated $1.21M.
  • Anika Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5007 holding.
  • UBS Group first reported a position in Anika Therapeutics in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Anika Therapeutics position peaked at $3.3M in Q1 2019.
  • 130 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.